Aurobindo Antibiotics Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 29-10-2024
- Paid Up Capital ₹ 1.00 Cr
as on 29-10-2024
- Company Age 4 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2023)
- Profit 46.53%
(FY 2023)
- Ebitda 46.62%
(FY 2023)
- Net Worth -3.11%
(FY 2023)
- Total Assets -3.11%
(FY 2023)
About Aurobindo Antibiotics
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 1.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Nityananda Kambam, Sadananda Sannareddy, Gopala Penupolu, and One other member serve as directors at the Company.
- CIN/LLPIN
U24110AP2020PTC115965
- Company No.
115965
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Oct 2020
- Date of AGM
25 Jul 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Visakhapatnam, Andhra Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Aurobindo Antibiotics?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nityananda Kambam  | Director | 26-Dec-2022 | Current |
| Sadananda Sannareddy | Director | 06-Oct-2020 | Current |
| Gopala Penupolu | Director | 06-Oct-2020 | Current |
| Bhanu Chavali | Director | 06-Oct-2020 | Current |
Financial Performance and Corporate Structure Insights of Aurobindo Antibiotics.
Aurobindo Antibiotics Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 46.53% increase in profit. The company's net worth dipped by a decrease of 3.11%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aurobindo Antibiotics?
In 2023, Aurobindo Antibiotics had a promoter holding of 100.00%. The company had 2 Subsidiaries. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Aurobindo Antibiotics?
Unlock and access historical data on people associated with Aurobindo Antibiotics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aurobindo Antibiotics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aurobindo Antibiotics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
